MAPT and Dravet syndrome: The presentation then focused on fluid (CSF, plasma) and imaging (MRI, PET) biomarkers of amyloidosis, tau pathology, and neurodegeneration and how they have shown excellent diagnostic performance in distinguishing symptomatic AD in adults with DS using data from the DABNI cohort (Carmona-Iragui et al., 2021; Fortea et al., 2018a, 2020).